This is the authors' abstract. We don't add key points for this paper.
There is evidence from randomised controlled studies that glucocorticoid corticosteroid therapy in Duchenne muscular dystrophy improves muscle strength and function in the short-term (six months to two years). The most effective prednisolone regime appears to be 0.75 mg/kg/day. In the short term, adverse effects were significantly more common but not clinically severe. Long-term benefits and hazards of glucocorticoid treatment cannot be evaluated from the currently published randomised studies. Non-randomised studies support the conclusions of functional benefits but also indicate clinically significant adverse effects of long-term treatment. These benefits and adverse effects have implications for future research studies and clinical practice.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Manzur et al. (2004) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: